itolizumab   Click here for help

GtoPdb Ligand ID: 9421

Synonyms: Alzumab® | T1h
Approved drug Immunopharmacology Ligand
itolizumab is an approved drug (DCGI (India; 2013))
Compound class: Antibody
Comment: Itolizumab is a first in class humanized IgG1 monoclonal antibody targeting T cell CD6. It is being developed by Biocon Limited for its anti-inflammatory potential in autoimmune conditions.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
References
1. Alonso R, Huerta V, de Leon J, Piedra P, Puchades Y, Guirola O, Chinea G, Montero E. (2008)
Towards the definition of a chimpanzee and human conserved CD6 domain 1 epitope recognized by T1 monoclonal antibody.
Hybridoma (Larchmt), 27 (4): 291-301. [PMID:18707547]
2. Dogra S, D S K, Budamakuntla L, Srinivas CR, Khopkar U, Gupta S, Shetty N, Pratap DV, Gopal MG, Rao TN et al.. (2015)
Long-term efficacy and safety of itolizumab in patients with moderate-to-severe chronic plaque psoriasis: A double-blind, randomized-withdrawal, placebo-controlled study.
J Am Acad Dermatol, 73 (2): 331-3.e1. [PMID:26183983]
3. Jayaraman K. (2013)
Biocon's first-in-class anti-CD6 mAb reaches the market.
Nat Biotechnol, 31 (12): 1062-3. [PMID:24316625]
4. Krupashankar DS, Dogra S, Kura M, Saraswat A, Budamakuntla L, Sumathy TK, Shah R, Gopal MG, Narayana Rao T, Srinivas CR et al.. (2014)
Efficacy and safety of itolizumab, a novel anti-CD6 monoclonal antibody, in patients with moderate to severe chronic plaque psoriasis: results of a double-blind, randomized, placebo-controlled, phase-III study.
J Am Acad Dermatol, 71 (3): 484-92. [PMID:24703722]
5. Rodriguez PC, Torres-Moya R, Reyes G, Molinero C, Prada D, Lopez AM, Hernandez IM, Hernandez MV, Martinez JP, Hernandez X et al.. (2012)
A clinical exploratory study with itolizumab, an anti-CD6 monoclonal antibody, in patients with rheumatoid arthritis.
Results Immunol, 2: 204-11. [PMID:24371585]